240 related articles for article (PubMed ID: 16152593)
1. Steroid hormone receptors and coregulators in endocrine-resistant and estrogen-independent breast cancer cells.
Sarvilinna N; Eronen H; Miettinen S; Vienonen A; Ylikomi T
Int J Cancer; 2006 Feb; 118(4):832-40. PubMed ID: 16152593
[TBL] [Abstract][Full Text] [Related]
2. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
Fleming FJ; Hill AD; McDermott EW; O'Higgins NJ; Young LS
J Clin Endocrinol Metab; 2004 Jan; 89(1):375-83. PubMed ID: 14715875
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.
Keeton EK; Brown M
Mol Endocrinol; 2005 Jun; 19(6):1543-54. PubMed ID: 15802375
[TBL] [Abstract][Full Text] [Related]
4. The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity.
Peterson TJ; Karmakar S; Pace MC; Gao T; Smith CL
Mol Cell Biol; 2007 Sep; 27(17):5933-48. PubMed ID: 17591692
[TBL] [Abstract][Full Text] [Related]
5. Expression of nuclear receptors and cofactors in human endometrium and myometrium.
Vienonen A; Miettinen S; Bläuer M; Martikainen PM; Tomás E; Heinonen PK; Ylikomi T
J Soc Gynecol Investig; 2004 Feb; 11(2):104-12. PubMed ID: 14980312
[TBL] [Abstract][Full Text] [Related]
6. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
[TBL] [Abstract][Full Text] [Related]
7. Changes in protein tyrosine phosphatase type IVA member 1 and zinc finger protein 36 C3H type-like 1 expression demonstrate altered estrogen and progestin effect in medroxyprogesterone acetate-resistant and estrogen-independent breast cancer cell models.
Pennanen PT; Sarvilinna NS; Purmonen SR; Ylikomi TJ
Steroids; 2009; 74(4-5):404-9. PubMed ID: 19146866
[TBL] [Abstract][Full Text] [Related]
8. High progesterone receptor concentration in a variant of the ZR-75-1 human breast cancer cell line adapted to growth in oestrogen free conditions.
van den Berg HW; Martin J; Lynch M
Br J Cancer; 1990 Apr; 61(4):504-7. PubMed ID: 2139575
[TBL] [Abstract][Full Text] [Related]
9. Gene expression changes during the development of estrogen-independent and antiestrogen-resistant growth in breast cancer cell culture models.
Pennanen PT; Sarvilinna NS; Ylikomi TJ
Anticancer Drugs; 2009 Jan; 20(1):51-8. PubMed ID: 19343000
[TBL] [Abstract][Full Text] [Related]
10. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms involved in the evolution of progestin resistance in human breast cancer cells.
Murphy LC; Dotzlaw H; Wong MS; Miller T; Murphy LJ
Cancer Res; 1991 Apr; 51(8):2051-7. PubMed ID: 1849041
[TBL] [Abstract][Full Text] [Related]
12. Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones.
Havrilesky LJ; McMahon CP; Lobenhofer EK; Whitaker R; Marks JR; Berchuck A
J Soc Gynecol Investig; 2001; 8(2):104-13. PubMed ID: 11336882
[TBL] [Abstract][Full Text] [Related]
13. Effects of estradiol and progestogens on human breast cells: regulation of sex steroid receptors.
Chen FP; Chien MH; Chen HY; Huang TS; Ng YT
Taiwan J Obstet Gynecol; 2013 Sep; 52(3):365-73. PubMed ID: 24075375
[TBL] [Abstract][Full Text] [Related]
14. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma.
Zhao S; Chen X; Lu X; Yu Y; Feng Y
Gynecol Oncol; 2007 Apr; 105(1):45-54. PubMed ID: 17240435
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of an estrogen receptor-regulated gene by first generation progestins requires both the progesterone receptor and estrogen receptor alpha.
Perkins MS; Louw-du Toit R; Jackson H; Simons M; Africander D
Front Endocrinol (Lausanne); 2022; 13():959396. PubMed ID: 36187129
[TBL] [Abstract][Full Text] [Related]
17. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
Girault I; Lerebours F; Amarir S; Tozlu S; Tubiana-Hulin M; Lidereau R; Bièche I
Clin Cancer Res; 2003 Apr; 9(4):1259-66. PubMed ID: 12684393
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters.
Giulianelli S; Vaqué JP; Soldati R; Wargon V; Vanzulli SI; Martins R; Zeitlin E; Molinolo AA; Helguero LA; Lamb CA; Gutkind JS; Lanari C
Cancer Res; 2012 May; 72(9):2416-27. PubMed ID: 22396492
[TBL] [Abstract][Full Text] [Related]
19. Expression of steroid receptor coactivators and corepressors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression.
Uchikawa J; Shiozawa T; Shih HC; Miyamoto T; Feng YZ; Kashima H; Oka K; Konishi I
Cancer; 2003 Nov; 98(10):2207-13. PubMed ID: 14601091
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of nuclear receptor corepressor (NCoR) in progestin-induced growth suppression of endometrial hyperplasia and carcinoma.
Kashima H; Horiuchi A; Uchikawa J; Miyamoto T; Suzuki A; Ashida T; Konishi I; Shiozawa T
Anticancer Res; 2009 Apr; 29(4):1023-9. PubMed ID: 19414341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
